Neurons in the brain produce lamin C but almost no lamin A, a consequence of the removal of prelamin A transcripts by miR-9, a brain-specific microRNA. We have proposed that miR-9-mediated regulation of prelamin A in the brain could explain the absence of primary neurological disease in Hutchinson-Gilford progeria syndrome, a genetic disease caused by the synthesis of an internally truncated form of farnesyl-prelamin A ( progerin). This explanation makes sense, but it is not entirely satisfying because it is unclear whether progerin-even if were expressed in neurons-would be capable of eliciting neuropathology. To address that issue, we created a new Lmna knock-in allele, Lmna HG-C , which produces progerin transcripts lacking an miR-9 binding site. Mice harboring the Lmna HG-C allele produced progerin in neurons, but they had no pathology in the central nervous system. However, these mice invariably developed esophageal achalasia, and the enteric neurons and nerve fibers in gastrointestinal tract were markedly abnormal. The same disorder, achalasia, was observed in genetically modified mice that express full-length farnesyl-prelamin A in neurons (Zmpste24-deficient mice carrying two copies of a Lmna knock-in allele yielding full-length prelamin A transcripts lacking a miR-9 binding site). Our findings indicate that progerin and full-length farnesyl-prelamin A are toxic to neurons of the enteric nervous system.
Introduction
Hutchinson-Gilford progeria syndrome (HGPS) is caused by a point mutation in exon 11 of LMNA, the gene for lamin C and prelamin A (the precursor to mature lamin A) (1, 2) . The HGPS mutation leads to the synthesis of a mutant form of prelamin A, progerin, with an internal deletion of 50 amino acids (1, 2) . This deletion does not affect protein farnesylation but eliminates the ZMPSTE24-mediated endoproteolytic cleavage step that would ordinarily convert farnesyl-prelamin A to mature lamin A (3) . The absence of the final cleavage step means that progerin retains its carboxyl-terminal farnesyl lipid anchor and cannot be converted to mature lamin A (3). The HGPS mutation has no effect on lamin C.
The synthesis of progerin is toxic to multiple tissues and is responsible for all of the disease phenotypes associated with HGPS (e.g. osteolytic lesions, slow growth, loss of subcutaneous adipose tissue, atherosclerosis in large arteries) (4) (5) (6) . Several of these phenotypes resemble those that occur with aging, but some features of physiologic aging, notably senile dementia, are absent in children with HGPS; consequently, HGPS is often referred to as a 'segmental' aging syndrome (7) (8) (9) . Several years ago, we developed Lmna knock-in mice (Lmna HG/+ ) (see Table 1 ) that A Lmna knock-in mutation that yields full-length prelamin A transcripts containing lamin C's 3′ UTR. Lacks introns 10 and 11 and therefore does not produce lamin C transcripts. The mutant prelamin A transcript lacks a miR-9 binding site and is therefore expressed in neurons.
Wild-type prelamin A Yes Expressed at high levels in peripheral tissues and in the brain. In the presence of ZMPSTE24, the prelamin A produced by this allele is converted to mature lamin A. Mice homozygous for this allele appear normal.
Lmna

5NT (12)
A Lmna knock-in mutation that yields full-length prelamin A transcripts containing a 5-bp mutation in prelamin A's 3′ UTR. Lacks introns 10 and 11 and therefore does not produce lamin C transcripts. The mutant prelamin A transcript lacks a miR-9 binding site and is therefore expressed in neurons.
Wild-type prelamin A Yes Expressed at high levels in peripheral tissues and in the brain. In the presence of ZMPSTE24, the prelamin A produced by this allele is converted to mature lamin A. Mice homozygous for this allele appear normal. but they lack obvious pathology in the central nervous system (CNS). We hypothesized that the absence of neuropathology in children with HGPS (and Zmpste24 −/− and Lmna HG/+ mice) could relate to low levels of prelamin A expression in the brain. We quickly found support for this hypothesis. Most cell types and tissues produce roughly equal amounts of lamin A and lamin C, but neurons in the brain produce large amounts of lamin C but little prelamin A/lamin A (17) . Indeed, the only cells in the brain that produce significant amounts of lamin A are meningeal cells and endothelial cells (17) . Because lamin C and prelamin A are splice isoforms of the same gene, we initially suspected that the preferential synthesis of lamin C in neurons would be caused by alternative splicing, but this was not the case. Prelamin A transcripts in the brain are eliminated by a microRNA (miR-9) (17). The 3′ UTR of prelamin A's transcript contains a single miR-9-binding site; lamin C's transcript does not contain a miR-9-binding site. MiR-9 is expressed at high levels in the brain and regulates neurogenesis by influencing the expression of multiple transcription factors (18) . When miR-9 expression is eliminated, the pathology in the CNS is severe. MiR-9 has many targets and has potent effects on cells; transfecting fibroblasts with miR-9 transforms the cells into neurons (19) . The 'physiologic rationale' for regulating prelamin A expression in the brain with miR-9 is not clear. Of note, microRNA expression surveys have revealed that miR-9-1, miR-9-2 and miR-9-3 are expressed at high levels in the brain, with only negligible expression in peripheral tissues (http://mirnamap.mbc.nctu.edu.tw/php/ mirna_entry.php?acc=MI0000467).We confirmed these findings in a recent paper (12) .
To study the in vivo relevance of miR-9 regulation of prelamin A, we recently created two Lmna knock-in alleles that produce prelamin A transcripts lacking an miR-9-binding site (12) . The first of the two knock-in alleles, Lmna
5NT
, yielded prelamin A transcripts with a 5-bp mutation in prelamin A's miR-9-binding site; the second, Lmna PLAO-UTR (here renamed Lmna PLAO-C ), encoded a prelamin A transcript in which prelamin A's 3′ UTR was replaced with lamin C's 3′ UTR ( (12) . Mir-9-mediated removal of prelamin A transcripts in neurons provides a plausible explanation for the absence of primary brain pathology in children with HGPS, but this explanation is not complete because it is uncertain whether progerin-even if were expressed in the brain-would elicit neurotoxicity. It is noteworthy that the liver and kidney of Lmna HG/+ mice produce abundant amounts of progerin yet are free of pathology (10, 11) . The Lmna HG/+ mice described earlier (10, 11) produce progerin transcripts containing the miR-9-binding site. For that reason, progerin expression in the brain of Lmna HG/+ mice was negligible (17) , making it impossible to use these mice to assess the toxicity of progerin in neurons.
In the current study, we sought to determine whether the expression of progerin in neurons would elicit neuropathology, and if so, which neurons are most affected. To address that issue, we created a new Lmna knock-in allele, Lmna HG-C , which is identical to the original Lmna HG allele except that it produces progerin transcripts harboring lamin C's 3′ UTR (and lacking the miR-9 binding site) ( Table 1) . We anticipated that this new Lmna knock-in allele would yield robust expression of progerin in neurons.
Results
Lmna knock-in mice that express progerin in neurons
We used a sequence-replacement gene-targeting vector to create a new Lmna knock-in allele, Lmna
HG-C
, that yields progerin transcripts containing lamin C's 3′ UTR (Fig. 1) . The Lmna HG-C allele is identical to the Lmna HG allele described earlier (10, 11) except that it contains lamin C's 3′ UTR and therefore lacks a miR-9-binding site. The Lmna HG-C allele is also identical to the Lmna PLAO-UTR allele (here designated Lmna PLAO-C ) (12) except that the Lmna HG-C allele encodes progerin rather than full-length prelamin A. All of the Lmna knock-in alleles lack introns 10 and 11 and therefore do not produce lamin C. The properties of the mutant alleles that we mention in this manuscript are described in Table 1 .
The Lmna PLAO-C allele yielded high levels of prelamin A transcripts and mature lamin A protein in both peripheral tissues and in the brain (reflecting an absence of miR-9-mediated regulation of prelamin A expression) (12) . The Lmna HG-C allele shared these properties; progerin was expressed in all tissues of Lmna HG-C/+ mice, including in the brain ( Fig. 2A) . The amount of progerin in the cerebral cortex was more than 10-fold greater in Lmna HG-C/+ mice than in Lmna HG/+ mice (where miR-9 regulation of progerin is intact) (Fig. 2B and D) . In contrast, the expression of progerin was robust in the lung of both Lmna HG-C/+ and Lmna HG/+ mice ( Fig. 2B and D) . The levels of progerin in Lmna HG-C/+ and Lmna HG/+ fibroblasts were similar ( Fig. 2C and D) . We also observed similar percentages of misshapen nuclei in Lmna HG-C/+
and Lmna HG/+ fibroblasts-and in Lmna HG/HG and Lmna HG-C/HG-C fibroblasts (Fig. 2E ). Lamin A expression in the cerebral cortex of wild-type mice was negligible (except in endothelial cells and meningeal cells) (Fig. 3A) . In contrast, the expression of progerin in neurons of the cerebral cortex, cerebellum and hippocampus of 1-monthold Lmna HG-C/HG-C mice was robust (in these mice, the only 'Lmna protein' is progerin) ( were viable but were invariably quite small (∼10 g at 4 weeks of age); all homozygotes died between 3 and 8 weeks of age (n = 21). We showed previously that the migration of cortical neurons during embryonic development is defective in Lmnb1 −/− and Lmnb2 −/− embryos, resulting in neuronal layering abnormalities in the cerebral cortex (20) (21) (22) (23) . No such pathology was present in 2-week-old Lmna HG-C/+ or Lmna HG-C/HG-C mice ( Fig. 4A and B).
The cellularity of the cortex in Lmna HG-C/+ mice appeared normal ( mice (n > 24) had a dilated esophagus ( Fig. 5 ) that often contained food. This phenotype was never observed in wild-type mice. The esophagus in Lmna HG-C/+ mice appeared yellow, reflecting markedly reduced amounts of muscle within the muscularis externa. In contrast, the esophagus in wild-type mice was pink-red, similar to the color of the intercostal muscles (Fig. 5 ). Stained sections of the esophagus in Lmna HG-C/+ mice revealed a cornified squamous epithelium and thinning of the inner circular and outer longitudinal layers of the muscularis externa ( Fig. 6 ). At 3 months of age, the thickness of the muscularis externa of the mid-esophagus in Lmna HG-C/+ mice was 0.08 ± 0.04 mm (versus 0.19 ± 0.04 mm in wild-type mice); at 7 months, the thickness of the muscularis externa was 0.04 ± 0.03 mm (versus 0.18 ± 0.03 mm in wild-type mice). This pathology is similar to that of achalasia in humans.
In achalasia, the failure of relaxation in the lower esophageal sphincter leads to dilatation of the esophagus, thinning of the muscularis externa and a cornified epithelial lining (24) . In addition, Lmna HG-C/+ mice invariably had a dilated cecum and proximal colon (Fig. 7) . Finding intestinal pathology in Lmna HG-C/+ mice was unexpected, and for that reason we considered it essential to validate our findings with a related but genetically distinct mouse model. As noted earlier, we documented very similar disease phenotypes in Lmna HG/+ mice (which accumulate progerin) and Zmpste24 −/− mice (which accumulate a farnesylated version of full-length prelamin A) (11, 14, 15, 25) . Given those findings, we suspected that Zmpste24 −/− mice might develop the same gastrointestinal pathology observed in Lmna HG-C/+ mice if they were capable of producing prelamin A in neurons. To test this idea, we bred Zmpste24 −/− mice harboring two copies of the Lmna PLAO-C allele (Zmpste24 −/− Lmna PLAO-C/PLAO-C ). As we had predicted,
Zmpste24
−/− Lmna PLAO-C/PLAO-C mice developed a markedly dilated, yellow esophagus (indistinguishable from the esophagus in Lmna HG-C/+ mice) ( Fig. 8A and B) . By microscopy, the pathology in Zmpste24
−/− Lmna PLAO-C/PLAO-C mice was similar: the esophagus was dilated, lined with a cornified epithelium, and manifested thinning and fibrosis of the muscularis externa. Zmpste24 Lmna PLAO-C/PLAO-C mice (Supplementary Material, Fig. S2 ), despite the fact that the neurons in these mice accumulate farnesylprelamin A (12) . No intestinal pathology was present in Zmpste24 −/− mice (where prelamin A expression in neurons is prevented by miR-9 regulation) or in Lmna PLAO-C/PLAO-C mice (n > 10) (where prelamin A in neurons is converted to mature lamin A) (12) . Also, no intestinal pathology was observed in Zmpste24 −/− mice carrying one or two copies of a Lmna knock-in allele, Lmna PLAO , which yields prelamin A transcripts containing prelamin A's miR-9 binding site ( Fig. 8C ) (13) .
Both Lmna HG-C/+ and Zmpste24 −/− Lmna PLAO-C/PLAO-C mice lacked the capacity to suppress neuronal expression of prelamin A; both produced a toxic version of prelamin A; and both had striking disease in the gastrointestinal tract. The parsimonious explanation for the intestinal pathology is that neuronal expression of progerin and farnesyl-prelamin A is toxic to enteric neurons. To explore this possibility, we examined whole mounts of the esophagus of wild-type and Lmna HG-C/+ mice stained with an antibody against the neuronal marker Protein gene product 9.5 (PGP9.5) (Fig. 9) . In Lmna HG-C/+ mice, PGP9.5 staining revealed few enteric neurons and nerve fibers in the esophagus (or elsewhere in the gastrointestinal tract), whereas PGP9.5 staining in wild-type mice was robust. Consistent with these findings, we observed reduced levels of the vesicular acetylcholine transporter (a marker for cholinergic neurons) in the esophagus of Lmna HG-C/+ mice (Fig. 10) . Interestingly, we observed reduced staining for c-Kit (a receptor tyrosine kinase that serves as a marker for interstitial cells of Cajal; ICC) in the gastrointestinal tract of Lmna HG-C/+ mice (Fig. 10) . A similar reduction in c-Kit and Lmna HG/+ mice. However, the progeria-like disease phenotypes were more severe in Lmna HG/+ mice (11, 26, 27) 
than in
Lmna HG-C/+ mice. For example, the body weights of adult Lmna HG/+ mice (11, 26, 27) were far lower than those of Lmna HG-C/+ mice in this study. Also, osteolytic lesions and rib fractures were never observed in Lmna HG-C/+ mice, whereas they were frequent in Lmna HG/+ mice (11) . Finally, some of the Lmna HG-C/+ mice survived for 12 months (despite the intestinal pathology), whereas Lmna HG/+ mice invariably died by 6-8 months of age (11) . Similarly, the progeria-like disease phenotypes were less severe in Zmpste24 
Discussion
We reported that miR-9 regulates prelamin A expression in neurons, and we proposed that miR-9 regulation of prelamin A expression might explain the absence of primary neuropathology in HGPS (12,17,23,28 ). This explanation was plausible but incomplete, simply because it remained unclear whether progerin-even if expressed in neurons-would elicit neuropathology.
In the current study, we addressed that issue by creating a new Lmna knock-in allele, Lmna HG-C , which yields progerin transcripts lacking the miR-9-binding site. We predicted that mice harboring the Lmna HG-C allele would express progerin in neurons. This prediction was upheld; Lmna HG-C/+ mice produced large amounts of progerin in the brain (>10-fold more than in Lmna HG/+ mice, where neuronal expression of progerin is suppressed by miR-9). Lmna HG-C/+ mice did not develop pathology in the CNS, but 100% of the mice developed an enlarged esophagus by 3-4 months of age. The esophageal pathology in Lmna HG-C/+ mice resembled that in humans with achalasia (29-31), an esophageal motility disorder caused by impaired relaxation of the lower esophageal sphincter. The esophagus in Lmna HG-C/+ mice had a cornified epithelial lining and severe thinning of the muscularis externa. Immunohistochemical studies also revealed reduced numbers of enteric neurons and associated nerve fibers. Similar pathology has been observed in humans with achalasia and in other genetic models of achalasia (30, 32, 33) . In contrast to our findings with Lmna HG-C/+ mice, we never encountered a dilated esophagus in Lmna HG/+ mice (11) , where the production of progerin in neurons is suppressed by miR-9 regulation (17).
In our study, progerin levels in the cerebral cortex were much higher in Lmna HG-C/+ mice than in Lmna HG/+ mice, reflecting the importance of miR-9 regulation of prelamin A expression in the brain (12, 17) . We did not observe large differences in progerin expression in other tissues (12) , consistent with the fact that miR-9 expression levels are low in most peripheral tissues (http://mirnamap.mbc. nctu.edu.tw/php/mirna_entry.php?acc=MI0000467). We suspect that the high levels of progerin expression in neurons of Lmna HG-C/+ mice are responsible for the achalasia phenotype that we observed. However, we cannot exclude the possibility that miR-9 is expressed in specific subpopulations of cells within selected peripheral tissues. If that were the case, it conceivably could be relevant to the disease phenotypes that we observed. Because the esophageal pathology in Lmna HG-C/+ mice was completely unexpected, we considered it essential to verify our findings with a related but genetically distinct mouse model. We reasoned that if the expression of progerin by neurons in Lmna HG-C/+ mice were responsible for the gastrointestinal tract pathology, then we should find the same pathology in mice that expressed full-length farnesyl-prelamin A in neurons. Indeed, this was the case; achalasia was invariably found in Zmpste24-deficient mice harboring two copies of the Lmna (where the farnesyl-prelamin A in neurons is converted to mature lamin A). The fact that neuronal expression of both progerin and full-length farnesyl-prelamin A led to the same pathology, achalasia, is consistent with earlier studies showing that the toxicities of the two proteins are similar in peripheral tissues (11, 15, 25, 34) . In our studies, whole-mount immunohistochemistry assays of the gastrointestinal tract of Lmna HG-C/+ mice revealed reduced numbers of enteric neurons and associated nerve fibers in the muscularis externa. Given that progerin is toxic for cells and tissues and given that the Lmna HG-C mutation was specifically designed to permit progerin expression in neurons, it seems quite likely that the production of progerin in neurons is responsible for the enteric nerve pathology that we encountered. In an earlier study, achalasia was observed in mice lacking Sprouty2 (35), a negative regulator of multiple receptor tyrosine kinases. In that case, whole-mount immunohistochemistry studies revealed hyperplasia of enteric neurons and disorganization of nerve fibers in the esophagus (35) . Recent studies have suggested that interstitial cells of Cajal (ICCs) play a role in the relaxation of the esophagus (36, 37) . [ICCs are pacemaker cells that control the contraction of smooth muscle cells in the gastrointestinal tract and mediate enteric motor responses.] In our studies, we found evidence of disease in ICCs (reduced expression of c-Kit in the gastrointestinal tract in Lmna HG-C/+ mice). Reduced esophageal ICC staining has also been observed in biopsy material from humans undergoing surgery for achalasia (38, 39) . In Lmna HG-C/+ and Zmpste24
−/−
Lmna PLAO-C/PLAO-C mice, we observed dilated intestines, cecum and colon in addition to the esophageal pathology. It is conceivable that changes in intestinal flora brought on by the achalasia contribute to the enlargement of the cecum/proximal colon in mice (40) (41) (42) . However, our immunohistochemistry studies showed that the pathology in the enteric nervous system was present in several segments of the gastrointestinal tract. The majority of humans with achalasia do not have significant pathology in the colon, but there have been examples of cases in which megaesophagus and megacolon co-exist (29, 43) . In some cases, the coexistence of achalasia and megacolon has been familial (29) .
In the current study, we showed that eliminating miR-9 regulation in the new progerin knock-in allele (Lmna HG-C ) resulted in large amounts of progerin expression in the CNS; however, progerin expression in neurons of Lmna HG-C/+ mice did not lead to obvious CNS pathology. Similarly, we found no CNS pathology in Zmpste24
−/− Lmna PLAO-C/PLAO-C mice. Consistent with these findings, we did not encounter pathology in forebrain-specific Zmpste24 knockout mice carrying two copies of Lmna PLAO-C allele;
those mice produce farnesyl-prelamin A in forebrain neurons (Jung et al. unpublished) . At this point, we do not understand why the expression of progerin in neurons has negligible effects in the CNS but striking effects in the gastrointestinal tract, but we suspect that neurons of the CNS are less susceptible to the toxicity of progerin. Our inability to find significant CNS pathology in Lmna HG-C/+ mice appears to be consistent with a recent manuscript from Baek et al. (44) ; they found negligible effects of human progerin in the brain of tetracycline-regulated transgenic mice with aberrant expression of the progerin open-reading frame in the brain, skin and bone. In those studies, the gastrointestinal tract was not examined. On the other hand, Miller et al. (45) found that overexpression of progerin in neurons derived from induced pleuripotent stem cells led to breakdown of neurites.
Could our mouse models of achalasia be relevant to the human disease? It would be reasonable to be skeptical, simply because the development of achalasia in our models required two types of mutations (one eliminating neuronal regulation of prelamin A by miR-9, and a second that led to the accumulation of a farnesylated version of prelamin A). The coexistence of both types of mutations in a human patient would be quite unlikely. In addition, achalasia in humans is not accompanied by disease phenotypes of progeria. Nevertheless, one could still argue that our findings could be relevant to human achalasia. At this point, no one understands why mammals evolved an efficient strategy for suppressing the expression of prelamin A transcripts and lamin A protein in neurons; however, this regulatory mechanism is conserved and presumably is important. One could speculate that mature lamin A, which is normally absent in neurons, could be toxic for enteric neurons (although to a lesser degree than progerin or farnesyl-prelamin A). While we never identified overt intestinal pathology in mice that produce mature lamin A in neurons (i.e. Lmna PLAO-C/PLAO-C mice), it is conceivable that the low-level toxicity of mature lamin A in enteric neurons is simply not apparent within the short life span of a laboratory mouse. In humans, achalasia is generally not detected until the 4th or 5th decade of life, and in most cases the underlying cause is utterly mysterious. If our speculation about low-level toxicity of mature lamin A in enteric neurons is accurate, then it would be quite reasonable to speculate that some cases of achalasia in humans could be caused by point mutations in prelamin A's miR-9-binding site. Both Lmna HG-C/+ and Lmna HG/+ mice express progerin in peripheral tissues, but the progeria-like disease phenotypes were less severe in Lmna HG-C/+ mice (11) . Similarly, progeria-like disease phenotypes were less severe in Zmpste24 lower amounts of progerin and farnesyl-prelamin A in certain cell types. In the current study, we found roughly similar levels of progerin in Lmna HG-C/+ and Lmna HG/+ fibroblasts, but it remains quite possible that Lmna HG-C/+ and Lmna HG/+ mice differ with respect to progerin expression in cell types that underlie osteolytic lesions, bone fractures and progressive inanition. Such expression differences need not to be largely significant; genetic and pharmacologic studies have shown that modest differences in progerin and prelamin A expression levels translate into substantial differences in quantifiable disease phenotypes and survival (11, 25, 27, 34) .
Materials and Methods
Generation of a new Lmna knock-in allele, Lmna
HG-C
To create the Lmna HG-C allele, we used a gene-targeting vector identical to the one used to create the Lmna HG allele (10, 11) , except that the sequences for prelamin A's 3′ UTR in the 5′ arm were replaced with lamin C's 3′ UTR. Lamin C's 3′ UTR was amplified with primers 5′-TGCAGCATCATGTAAGGCCCAGCCCA CAAGGGTA-3′ and 5′-GACACCACAGCATCTGGCATTCCAAAACAT.
The new 3′ UTR sequences were introduced into the 5′ arm of the vector with the In-Fusion Advantage PCR cloning kit (Clontech). The integrity of the gene-targeting vector was verified by restriction endonuclease digestion and DNA sequencing. The gene-targeting vector was linearized with NotI and electroporated into embryonic stem (ES) cells (strain 129/OlaHsd). To identify targeted clones, long-range PCR on the 5′ end was performed with primers 5′-TCGAATCCGCATTGACAGCCTCT-3′ ( primer A in Fig. 1A ) and 5′-AAGCGAAGGAGCAAAGCTGCTA-3′ (primer NeoR). Long-range PCR on the 3′ end was performed with primers 5′-TGCTCCTGCCGAGAAAGTAT-3′ ( primer NeoF in Fig. 1A ) and 5′-AAAGTTCAGGCCCTTCTGGT-3′ (primer B). Targeted ES cells were used to create male chimeric mice, which were bred with C57BL/6 females to produce heterozygous mice (Lmna ). Mice were genotyped by PCR with genomic DNA from tail biopsies and oligonucleotide primers 5′-AGTACAACCTGCGCTCACGC-3′ ( primer C) and 5′-ATGTGTCTG CCCCTGAAAAC-3′ ( primer D) (Fig. 1A) . The wild-type Lmna allele yields a 1488-bp PCR product, whereas the Lmna HG-C allele yields a 249-bp product.
Additional genetically modified mice
Zmpste24 knockout mice (Zmpste24
) and mice harboring other Lmna knock-in alleles (Lmna HG , Lmna PLAO , Lmna PLAO-UTR ) have been described previously (10-13) ( Table 1) . In this study, the Lmna PLAO-UTR allele (12) was renamed the Lmna PLAO-C allele. All mice in this study were weaned at 21 days of age and housed in a virus-free barrier facility with a 12-h light-dark cycle. Mice were fed a chow diet containing 4.5% fat.
Analysis of mouse embryonic fibroblasts
Primary mouse embryonic fibroblasts (MEFs) were prepared from E14.5 embryos (46,47) and plated onto 6-well plates. To gauge the frequency of nuclear shape abnormalities in MEFs, passage 2-3 MEFs were grown on coverslips and then fixed and permeabilized (10, 25, 26, 48, 49) . The slides were incubated with antibodies against lamin A (1:200, sc-20680, Santa Cruz Biotechnology) for 2 h. Binding of the primary antibody was detected with Alexa Fluor 568-conjugated anti-rabbit antibody (1:800, Jackson ImmunoResearch Laboratories), and DNA was stained with DAPI. Images were obtained on a Zeiss LSM700 laser-scanning microscope, and nuclear shape abnormalities were assessed in a blinded fashion (4 fibroblast cell lines/genotype; >300 cells examined/cell line). 
Protein extraction and western blots
Urea-soluble cell extracts from early-passage MEFs and tissues (10, 25, 34, 48, 49) were size fractionated on 4-12% gradient polyacrylamide Bis-Tris gels (Invitrogen), and the proteins were transferred to nitrocellulose membranes for western blotting. Antibody dilutions were 1:200 for anti-lamin A/C goat IgG (sc-6215, Santa Cruz Biotechnology); 1:1000 for anti-actin goat IgG (sc-1616, Santa Cruz Biotechnology); and 1:5000 for IRDye 700-and 800-anti-goat IgG (Rockland Immunochemicals). The IRDye-conjugated antibodies were detected with an Odyssey infrared imaging scanner.
Histology and immunofluorescence microscopy
Mouse tissues were fixed for 4 h in 10% paraformaldehyde (PFA), dehydrated for 24 h in 70% ethanol and embedded in paraffin. Sections (5 μm) were stained with hematoxylin and eosin or with trichrome. For immunofluorescence microscopy, tissues were embedded in Sakura Tissue-Tec OCT compound, frozen on dry ice and 10-μm-thick sections were cut with a cryostat. Slides were first fixed in ice-cold methanol followed by a quick rinse with acetone and permeabilization with PBS containing 0.1% Tween-20. In some cases, sections were incubated in M.O.M. Mouse Ig Blocking Reagent (Vector Laboratories). Slides were incubated overnight at 4°C with primary antibodies [a mouse monoclonal antibody-specific for lamin A (Millipore, 1:400); a goat polyclonal antibody against lamin A/C (Santa Cruz, 1:400); a rabbit monoclonal antibody against caspase 3, (Cell Signaling, 1:100)] diluted in blocking buffer containing 0.1% Triton X-100 (12) . Alexa Fluor-labeled secondary antibodies were incubated in a similar fashion for 0.5-1 h. After washing the slides, cells were fixed with 4% PFA for 10 min, incubated in PBS/DAPI for 10 min to stain DNA and mounted with Prolong-Gold Antifade reagent (Invitrogen). Light microscopy images were captured with a Leica MZ6 dissecting microscope [a Plan 0.5× objective (air)] with a DFC290 digital camera (Leica) and a Nikon Eclipse E600 microscope (12) . Confocal microscopy was performed with a Zeiss LSM700 laser-scanning confocal microscope (12). Whole-mount studies and confocal immunofluorescence microscopy
To prepare whole mounts of intestine for immunohistochemistry, tissues were pinned with the mucosa facing upward to the Sylgard elastomer base of a dissecting dish containing fresh KRB, and the mucosa was removed by sharp dissection. Strips of tunica muscularis were stretched to 110% of the resting length and width; the tissues were fixed in either acetone (4°C, 30 min) or 4% (w/v) paraformaldehyde (room temperature, 1 h). After fixation, tissues were washed overnight in phosphate-buffered saline (PBS; 0.01 M, pH 7.2) and rewashed with fresh PBS the following day (4 times for 1 h). Tissues were subsequently incubated in 1% bovine serum albumin for 1 h and then incubated for 48 h at 4°C with antibodies against Protein gene product 9.5 (Ultraclone), vesicular acetylcholine transporter (Millipore), or c-Kit (R&D Systems). Binding of primary antibodies was detected with Alexa Fluor-labeled secondary antibodies (Molecular Probes). Tissues were examined with a Zeiss LSM 510 Meta confocal microscope (Zeiss, Germany). Final images were constructed using Zeiss LSM 5 Image Examiner software and processed in Adobe Photoshop 7.0 and Corel Draw 7.0. For the whole-mount studies, mice with achalasia (and control mice) were shipped to the University Nevada in four shipments between June 2013 and April 2014 (4-7 mice/shipment).
